// App-Quantinova.ai

: Phase 3 KEYNOTE-905/EV-303: Perioperative pembrolizumab (pembro) or pembro + enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC).

Researchers

Presenter

  • Andrea Necchi

Principal Investigators

  • Jens Bedke

  • Matt D. Galsky

  • Neal D. Shore

  • Elizabeth R. Plimack

  • Evanguelos Xylinas

  • Calvin Jia

  • Tammy Hennika

  • Blanca Homet Moreno

  • Alfred Alfred Witjes

Medical Centers

  • Department of Medical Oncology, San Raffaele Scientific Institute, Milan, Italy

  • Vita-Salute San Raffaele University,

  • Bichat-Claude Bernard Hospital, Assistance Publique–Hôpitaux de Paris, Université Paris Cité, Paris, France

  • Radboud University, Nijmegen, Netherlands

  • Fox Chase Cancer Center, Temple Health, Philadelphia, PA

  • Eberhard Karls University, Tubingen, Germany

  • Carolina Urologic Research Center, Myrtle Beach, SC

  • Icahn School of Medicine at Mount Sinai, New York, NY

Locations

  • Germany

  • Netherlands

  • Italy

  • France

  • United States

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bladder Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Enfortumab vedotin

  • Pembrolizumab

  • Cisplatin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT03924895

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved